Drugs and Devices

FDA approves treatment of non-small cell lung cancer

The U.S. Food and Drug Administration (FDA) has approved Xalkori (crizotinib) to treat patients with late-stage non-small cell lung cancers who express the abnormal anaplastic lymphoma kinase (ALK) gene. Read more.

Related Articles:

Leave a Reply

You have to agree to the comment policy.